Scaling up – how space is the key ingredient to superpower status

7 August 2023
labs_building_stock_2022_large

An Expert View from Katie Nelson, senior asset manager, and Mairi Dillon, ecosystem manager, at Kadans Science Partner.

The government's ambition to solidify the UK's status as a scientific superpower has been widely discussed, but what does this aspiration truly involve? In essence, it requires far more than just a title – it demands a financial commitment and measures to enhance the UK's appeal to global talent and investment. This strategic move will empower the UK to enhance its infrastructure and expertise, both of which are pivotal for industry growth.

The components of this industry, including physical assets, real estate, and diverse scientific infrastructure, alongside the skilled workforce operating within these facilities and driving industry advancement, will ultimately bridge the gap between the lofty 'superpower' label and genuine achievement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical